admin

admin

Rese Cel Autoimmune Follow Up Reaches One Year

Cabaletta disclosed updated single-arm rese-cel outcomes across autoimmune cohorts. Six of six dermatomyositis patients maintained immunomodulator-free moderate-to-major TIS responses at one year. The signal is clinically meaningful but small-cohort selection, optional biopsies and lack…

SRTD Names Matthias Alder Chief Executive

Recovered source-gap leadership item: SRTD Biotech identified Matthias Alder as its newly appointed CEO in its November 9 seed-financing announcement. The exact effective date, predecessor and reason for the appointment were not disclosed.